Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco
businesswire.com
news
2022-10-19 00:00:00

October 19, 2022 06:00 AM Eastern Daylight Time AUSTIN, Texas, SOUTH SAN FRANCISCO & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira Immunologics ('Triumvira'), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, Calif. for Triumvira to manufacture its own cell therapy candidates within the company's pipeline.
